description) The investigators propose to apply state-of-the-art pharmacogenetic and pharmacoepidemiologic research methods and two large pharmacoepidemiologic databases to assess the genetically-mediated role of prescription and OTC medications in the etiology of human birth defects. A particular focus relates to the increased risk of a common birth defect, persistent pulmonary hypertension (PPHN) of the newborn, following exposure late in pregnancy to nonsteroidal anti-inflammatory drugs (NSAIDs), and particularly ibuprofen, a drug that is among the most commonly used agents in pregnancy.
In aim 1, the investigators will apply data from an ongoing epidemiologic study of PPHN to test the hypothesis that this increased risk is related to genetically mediated factors involved in the metabolism of NSATDs.
In aim 2, they propose to use sophisticated technologic approaches to identify mutations in the CYP2D6, CYP3A4, and CYP3A7 and other gene promoters that modify developmental and tissue-specific expression of those genes in the fetus and newborn. Once polymorphisms are identified, the investigators will systematically evaluate their possible etiologic roles in humans by applying these new tools to current and future data collected by the SEU-BDS and the CDC-NBDPS, two large and unique epidemiologic birth defect studies that collect both genetic material and detailed information on antenatal drug exposures.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Research Project (R01)
Project #
5R01ES010855-02
Application #
6382412
Study Section
Special Emphasis Panel (ZHD1-RRG-K (02))
Program Officer
Gray, Kimberly A
Project Start
2000-08-01
Project End
2005-07-31
Budget Start
2001-08-01
Budget End
2002-07-31
Support Year
2
Fiscal Year
2001
Total Cost
$705,769
Indirect Cost
Name
Boston University
Department
Public Health & Prev Medicine
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02118
Li, Dan; Gaedigk, Roger; Hart, Steven N et al. (2012) The role of CYP3A4 mRNA transcript with shortened 3'-untranslated region in hepatocyte differentiation, liver development, and response to drug induction. Mol Pharmacol 81:86-96
Melen, Erik; Kho, Alvin T; Sharma, Sunita et al. (2011) Expression analysis of asthma candidate genes during human and murine lung development. Respir Res 12:86
Sharma, Sunita; Tantisira, Kelan; Carey, Vincent et al. (2010) A role for Wnt signaling genes in the pathogenesis of impaired lung function in asthma. Am J Respir Crit Care Med 181:328-36
Kho, Alvin T; Bhattacharya, Soumyaroop; Tantisira, Kelan G et al. (2010) Transcriptomic analysis of human lung development. Am J Respir Crit Care Med 181:54-63
Du, Rose; Tantisira, Kelan; Carey, Vincent et al. (2009) Platform dependence of inference on gene-wise and gene-set involvement in human lung development. BMC Bioinformatics 10:189
Leeder, J S (2009) Developmental pharmacogenetics: a general paradigm for application to neonatal pharmacology and toxicology. Clin Pharmacol Ther 86:678-82
Adjei, Araba A; Gaedigk, Andrea; Simon, Stephen D et al. (2008) Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res A Clin Mol Teratol 82:155-65
Hernandez-Diaz, Sonia; Werler, Martha M; Mitchell, Allen A (2007) Gestational hypertension in pregnancies supported by infertility treatments: role of infertility, treatments, and multiple gestations. Fertil Steril 88:438-45
Gaedigk, Andrea; Baker, Darren W; Totah, Rheem A et al. (2006) Variability of CYP2J2 expression in human fetal tissues. J Pharmacol Exp Ther 319:523-32
Hobson, Grace M; Huang, Zhong; Sperle, Karen et al. (2006) Splice-site contribution in alternative splicing of PLP1 and DM20: molecular studies in oligodendrocytes. Hum Mutat 27:69-77

Showing the most recent 10 out of 27 publications